Blackstone Life Sciences has entered into a collaboration with Moderna, Inc., providing up to $750 million to fund Moderna’s influenza (“flu”) program. This financing aims to support Moderna in advancing a broad and diverse pipeline of mRNA medicines and launching multiple vaccine products in the next few years.